EU/3/09/643: Orphan designation for the treatment of Rett syndrome

Desipramine chlorhydrate

Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in July 2017 on request of the sponsor.

On 12 June 2009, orphan designation (EU/3/09/643) was granted by the European Commission to Targeon SAS, France, for desipramine chlorhydrate for the treatment of Rett syndrome.

In November 2015, Targeon SAS changed name to Orphelia Pharma SA.

Key facts

Active substance
Desipramine chlorhydrate
Intented use
Treatment of Rett syndrome
Orphan designation status
EU designation number
Date of designation

Orphelia Pharma SA
65 rue Rambuteau
75004 Paris
Tel. +33 1 4277 0818

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating